Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2012 | short review | Ausgabe 4/2012

memo - Magazine of European Medical Oncology 4/2012

Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 4/2012
Autoren:
Ming Chi, MD, MSCI, FACP Assoc. Prof. Igor Puzanov

Abstract

In the past few decades, many advances have been witnessed in the development of personalized molecular therapies, especially in the areas of melanoma and nonsmall cell lung cancer (NSCLC) among all other medical oncology fields. These therapies can be roughly divided into three categories at present: (1) targeting membrane-bound receptor tyrosine kinase (RTK), using either monoclonal antibodies or tyrosine kinase inhibitor (TKI), (2) targeting intracellular mitogen-activated protein kinase (MAPK) pathway, and (3) targeting intracellular phosphoinositide 3-kinase (PI3K) pathway. Currently, melanoma research focuses on MAPK pathway, spending efforts to clarify the intricate interactions in RAS–MEK–ERK-signaling cascades, whereas in the field of NSCLC, most achievements have been made targeting RTKs. This review will discuss the recent movements of drug development in these two areas, specifically BRAF and MEK inhibitors in melanoma, and ELM4-ALK inhibitors in lung cancer, along with the mechanisms of drug resistance and potential future strategies.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2012

memo - Magazine of European Medical Oncology 4/2012Zur Ausgabe